(VIANEWS) – AKWEL (AKW.PA), VASTNED BELGIUM (VASTB.BR), SAMSE (SAMS.PA) are the highest payout ratio stocks on this list.
We have collected information about stocks with the highest payout ratio at the moment. The payout ratio in itself isn’t a promise of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. AKWEL (AKW.PA)
79.32% Payout Ratio
Akwel SA manufacture of automotive and heavy goods vehicle components in France and internationally. It offers fluid management, mechanisms, and structural parts for electric vehicles. The company's products include body pipes, flow regulation valves, anti-return valves, pulsation dampeners or temperature, and pressure sensors; air distributors, turbo air intake and output pipes and exchangers, exhaust gas recirculation pipes, and cylinder head covers. It also offers electronic management of hardware, software, transfer, storage, reheating, and pumping systems. The company was formerly known as MGI Coutier SA and changed its name to AKWEL in June 2018. The company was founded in 1972 and is headquartered in Champfromier, France. Akwel SA is a subsidiary of COUTIER DEVELOPPEMENT.
Earnings Per Share
As for profitability, AKWEL has a trailing twelve months EPS of €0.57.
PE Ratio
AKWEL has a trailing twelve months price to earnings ratio of 23.02. Meaning, the purchaser of the share is investing €23.02 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.61%.
Moving Average
AKWEL’s worth is way below its 50-day moving average of €16.00 and way under its 200-day moving average of €16.22.
Sales Growth
AKWEL’s sales growth for the current quarter is 12.4%.
More news about AKWEL.
2. VASTNED BELGIUM (VASTB.BR)
78.85% Payout Ratio
Vastned Retail Belgium is a public regulated real estate company (RREC), the shares of which are listed on Euronext Brussels (VASTB). Vastned Retail Belgium invests exclusively in Belgian commercial real estate, more specifically in prime retail properties located on the best shopping streets in the major cities of Antwerp, Brussels, Ghent and Bruges. Furthermore, the real estate portfolio consists of inner-city shops outside of the premium cities, high-end retail parks and retail warehouses.
Earnings Per Share
As for profitability, VASTNED BELGIUM has a trailing twelve months EPS of €2.79.
PE Ratio
VASTNED BELGIUM has a trailing twelve months price to earnings ratio of 11. Meaning, the purchaser of the share is investing €11 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.29%.
Moving Average
VASTNED BELGIUM’s value is under its 50-day moving average of €30.87 and higher than its 200-day moving average of €30.02.
Yearly Top and Bottom Value
VASTNED BELGIUM’s stock is valued at €30.70 at 07:10 EST, under its 52-week high of €34.10 and way higher than its 52-week low of €25.10.
More news about VASTNED BELGIUM.
3. SAMSE (SAMS.PA)
54.72% Payout Ratio
Samse SA distributes building materials and tools in France. The company offers public works, roads, and sanitation products; construction materials and structural works; plaster, ceiling, and insulation; frame and roof; wood and panels; doors, windows, and joinery; floor and wall coverings; electricity, plumbing, sanitary, and heating; terrace and garden products, as well as tools, materials, hardware, and security. It serves customers through approximately 80 points of sales in Auvergne-Rhône-Alpes, Paca, and Gard. The company was founded in 1920 and is headquartered in Grenoble, France. Samse SA is a subsidiary of Dumont Investissement.
Earnings Per Share
As for profitability, SAMSE has a trailing twelve months EPS of €13.74.
PE Ratio
SAMSE has a trailing twelve months price to earnings ratio of 13.79. Meaning, the purchaser of the share is investing €13.79 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.27%.
Sales Growth
SAMSE’s sales growth is 8% for the ongoing quarter and 8% for the next.
Volume
Today’s last reported volume for SAMSE is 54 which is 76.82% below its average volume of 233.
Yearly Top and Bottom Value
SAMSE’s stock is valued at €189.50 at 07:10 EST, way below its 52-week high of €220.00 and way above its 52-week low of €160.00.
Moving Average
SAMSE’s worth is higher than its 50-day moving average of €188.58 and above its 200-day moving average of €179.37.
More news about SAMSE.
4. SPBK 1 NORDMØRE (SNOR.OL)
50.15% Payout Ratio
SpareBank 1 Nordmøre provides various banking services in Norway. The company offers savings and deposit accounts; car, motorcycle, boat, and construction loans; and mortgages. It also provides business insurance products, which include liability, auto, mortgage, operating loss, asset, commercial, and project insurance products; personal insurance products, such as life, travel, and accidental insurance products; pension products; bank cards; payment and debt collection services; and mobile and online banking services. In addition, the company offers bank guarantees, trade credit products, and operating credit products for agriculture, as well as factoring, leasing, and repayment products and services. The company was founded in 1835 and is based in Kristiansund, Norway. SpareBank 1 Nordmøre is a subsidiary of SpareBank 1 Gruppen AS.
Earnings Per Share
As for profitability, SPBK 1 NORDMØRE has a trailing twelve months EPS of kr9.31.
PE Ratio
SPBK 1 NORDMØRE has a trailing twelve months price to earnings ratio of 13.21. Meaning, the purchaser of the share is investing kr13.21 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.57%.
Volume
Today’s last reported volume for SPBK 1 NORDMØRE is 43 which is 96.22% below its average volume of 1140.
Moving Average
SPBK 1 NORDMØRE’s worth is under its 50-day moving average of kr126.34 and under its 200-day moving average of kr126.03.
Revenue Growth
Year-on-year quarterly revenue growth grew by 52.3%, now sitting on 771M for the twelve trailing months.
More news about SPBK 1 NORDMØRE.
5. SANOFI (SAN.PA)
50% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.84.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 14.98. Meaning, the purchaser of the share is investing €14.98 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.77%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SANOFI’s EBITDA is 25.72.
Sales Growth
SANOFI’s sales growth is 11.3% for the present quarter and 3.1% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 5.2% and 1.2%, respectively.
Yearly Top and Bottom Value
SANOFI’s stock is valued at €102.44 at 07:10 EST, below its 52-week high of €106.66 and way above its 52-week low of €76.45.
More news about SANOFI.
